Northwest Biotherapeutics Reported Earnings

Northwest Biotherapeutics (NWBO) reported a loss of $0.01 per share on revenue of $0.81 million for the . . Revenue grew 516.03% on a year-over-year basis.

Northwest Biotherapeutics Inc is a development stage biotechnology company engaged in the development of immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies.